Journal of Hebei Medical University

Previous Articles     Next Articles

Clinical effect of terbutaline combined with azithromycin in the treatment of mycoplasma pneumoniae pneumonia

  

  1. Department of Pediatrics, Qinhuangdao Maternal and Child Health Hospital,
    Hebei Province, Qinhuangdao 066000, China
  • Online:2019-07-25 Published:2019-07-16

Abstract: [Abstract]〓Objective〖HTSS〗〓To observe the clinical effect of terbutaline combined with azithromycin in the treatment of mycoplasma pneumoniae pneumonia(MPP).
〖HTH〗〖WTHZ〗Methods〖HTSS〗〓A total of 116 cases of children with MPP were selected as the research object in our hospital. The patients were randomly divided into observation group and control group with 58 cases in each group. Patients in both groups were given azithromycin sequential therapy, and patients in the observation group were given terbutaline sulfate as well. The extinction time of symptoms and signs, the length of hospital stay, the clinical curative effect, the adverse reactions and the levels of interleukin6(IL6), tumor necrosis factorα(TNFα), Creactive protein(CRP), granulocytemacrophage colony stimulating factor(GMCSF) and CXC chemokine ligand 8(CXCL8) were compared between the two groups.
〖HTH〗〖WTHZ〗Results〖HTSS〗〓The extinction time of symptoms and signs and the time of hospitalization of the observation group were significantly shorter than that of the control group, and the difference was statistically significant(P<005). The clinical efficacy of the observation group was better than that of the control group, and the total effective rate was higher than that of the control group(P<005). After treatment, the levels of GMCSF, CXCL8, IL6, TNFa and CRP in the two groups were lower than those before treatment, and the levels of GMCSF, CXCL8, IL6, TNFα and CRP in the observation group were lower than those of the control group(P<005). There was no significant difference in the incidence of adverse reactions between the two groups(P>005).
〖HTH〗〖WTHZ〗Conclusion〖HTSS〗〓Terbutaline combined with Azithromycin sequential therapy in the treatment of MPP in children has synergistic effect. It can inhibit inflammation, reduce the expression levels of GMCSF, CXCL8 and related inflammatory factors, improve bronchial stenosis, reduce airway hyperresponsiveness, alleviate clinical symptoms and shorten treatment time. It is worthy of clinical application.

Key words: pneumonia, mycoplasma; azithromycin, terbutaline